Conférences - Pharmacologie et développement des médicaments - États-Unis

Conference-Service.com met à la disposition de ses visiteurs des listes de conférences et réunions dans le domaine scientifique. Ces listes sont publiées pour le bénéfice des personnes qui cherchent une conférence, mais aussi, bien sûr, pour celui des organisateurs. Noter que, malgré tout le soin que nous apportons à la vérification des données entrées dans nos listes, nous ne pouvons accepter de responsabilité en ce qui concerne leur exactitude ou étendue. Pensez donc à vérifier les informations présentées avec les organisateurs de la conférence ou de la réunion avant de vous engager à y participer!

Les organisateurs peuvent soumettre une réunion ou une conférence pour inclusion dans nos listes, et ceci gratuitement.

1.
 
Project management tools to improve productivity and compliance in Analytical laboratories
ID
789825
Dates
18 fév 2016 - 19 fév 2016
Lieu
San Francisco, États-Unis
Résumé
The pressure has been mounting in the pharma and biopharma industries in recent years to do more with less. Analytical laboratories are no exception to this trend. Work piles up while personnel have been cut or remain stagnant. Accelerated timelines further strain resources. Constant firefighting and band-aiding results in errors as well as compliance violations. It can be argued that the cost of non-compliance is more than that of compliance.Note: Use coupon code NB5SQH8N and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
project management tools, analytical testing laboratories, Analytical laboratories
2.
 
Validation, Verification and Transfer of Analytical Methods (Understanding and implementing guidelines from FDA/EMA, USP and ICH)
ID
789857
Dates
18 fév 2016 - 19 fév 2016
Lieu
San Francisco, États-Unis
Résumé
Analytical methods and procedures should be validated to ensure reliability, consistency and accuracy of analytical data. Compendial methods should be verified to demonstrate the suitability of laboratories to successfully run the method and when methods are transferred between laboratories successful transfer should be demonstrated through testing. In case a laboratory wants to use an alternative method instead of a compendial method, equivalency of the alternative method to the compendial method should be demonstrated.Note:Use coupon code NB5SQH8N and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
Laboratory compliance, Analytical methods, data, procedures, compendial methods, Method validation and transfer, equivalency testing
3.
 
LDN 2016 — The LDN 2016 AIIC Conference
ID
725325
Dates
19 fév 2016 - 21 fév 2016
Lieu
Orlando, États-Unis
Résumé
The LDN AIIC 2016 Conference is produced by the LDN Research Trust, a non-profit, Registered Charity dedicated to raising awareness as well as funding research and clinical trials of LDN as a treatment for Crohn's Disease, Colitis, Autism, IBS, Lupus, Fibromyalgia, Rheumatoid, Arthritis, Chronic Pain and other auto-immune diseases. The central role of the conference is to review, compare and contrast the most recent LDN-related data and treatments. It also offers compelling examples, experiences and case studies from many of the world’s leading experts, practitioners and patients who are using LDN to achieve positive, and in many cases, life-changing results.
Contact
Jim Warner;     Tél.: [+1 770-663-8803];     Email.: jim.warner@ldn2016.com
Sujets
LDN, MS, Chrohns, Fibromyalgia, Chronic Pain, Autism, Colitis, ME/CFS
Sujets apparentés
4.
 
G Protein-Coupled Receptors: Structure, Signaling and Drug Discovery
ID
739986
Dates
21 fév 2016 - 25 fév 2016
Lieu
Keystone, États-Unis
Résumé
The field of G protein-coupled receptors has recently seen major advances in high-resolution structure determination, as well as the validation of novel paradigms of drug action, such as allosteric modulation and biased agonism, as likely universal mechanisms. These studies are opening new insights into the diversity of this receptor superfamily, teaching us new lessons in receptor functionality and hinting at novel avenues to investigate. At the same time, we are seeing exciting discoveries in GPCR intracellular signaling and physiology. The timing is right to bring together researchers in these different areas. This Keystone Symposia meeting will focus on the interplay between these discoveries and how they are being used to advance GPCR-based research toward improved clinical outcomes. 
Sujets apparentés
5.
 
Effectively Addressing and Remediating FDA's Form 483 Findings, Warning Letters and Consent Decree Compliance Issues
ID
789878
Dates
22 fév 2016 - 23 fév 2016
Lieu
Orlando, États-Unis
Résumé
This seminar will guide the attendee in effectively handling, addressing and remediating FDA's and other related compliance issues associated such as FDA's Form 483, Warning Letter and Consent Decree Compliance Findings. An effective handling and resolution of Compliance issues will prevent further disciplinary actions such as an FDA's Warning Letter or a formal Consent Decree which ends with a costly impact, fines and possible injunctions by the FDA.Note: Use coupon code NB5SQH8N and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
FDA Form 483 Warning Letters, FDA Consent Decree, FDA injunction, Code of Federal Regulations, FDA Form 483 Seminar
6.
 
Ubiquitin Research & Drug Discovery Conference
ID
744985
Dates
24 fév 2016 - 25 fév 2016
Lieu
San Diego, États-Unis
Résumé
Recent breakthroughs in research, such as the phosphorylation of ubiquitin, have exciting implications for drug discovery. This meeting seeks to create a forum for scientists to discuss advances in structural insights, novel drug targets, and other hot topics in ubiquitin-pathway research. Attend this event not only for updates on the latest scientific research, but also for networking sessions between colleagues from both industry and academia in order to get the most comprehensive exchange of ideas. 
7.
 
Enzymes in Drug Discovery Summit
ID
744895
Dates
24 fév 2016 - 26 fév 2016
Lieu
San Diego, États-Unis
Résumé
The summit will bring together an exciting balance of industry and academia, so that delegates have the unique opportunity to network with colleagues from different sectors and gain fresh perspective on the various research happening.
8.
 
Epigenetic Enzymes in Drug Discovery Summit
ID
744905
Dates
25 fév 2016 - 26 fév 2016
Lieu
San Diego, États-Unis
Résumé
Epigenetic Enzymes in Drug Discovery Summit will bring together an exciting balance of industry and academia, so that delegates have the unique opportunity to network with colleagues from different sectors and gain fresh perspective on the various research happening.  
9.
 
Protease Inhibitors in Drug Discovery Conference
ID
744900
Dates
25 fév 2016 - 26 fév 2016
Lieu
San Diego, États-Unis
Résumé
Though protease inhibitors hold great therapeutic promise in areas such as inflammation, cardiovascular diseases, and cancer, researchers in the field are still overcoming the challenge of specificity for drug design. This meeting will provide a forum for scientists from both industry and academia to share recent advances in protease inhibitor research, from biological functions to translational aspects for drug discovery. Speakers will cover topics such as regulation of proteases by exosites, deubiquitinating enzymes, membrane-associated proteolysis, and many more. In addition to cutting-edge scientific presentations, attendees will be able to form new connections during dedicated networking sessions.
10.
 
Seminar on HIPAA 2016 - Upcoming Changes - Revenue Growth and HIPAA Dangers - Market Vigorously and Comply with HIPAA at New Orleans, LA
ID
773970
Dates
25 fév 2016 - 26 fév 2016
Lieu
New Orleans, États-Unis
Résumé
Paul Hales, with a team of expert advisors and practical field testers, have created a method of making all HIPAA regulations accessible to the everyday person, explained in plain language with exact citations to each regulation for the benefit of the organizations' legal counsel who may not be experienced in HIPAA.
Contact
Event Manager;     Tél.: [0800 4479407];     Email.: support@globalcompliancepanel.com
Sujets
HIPAA 2016, HIPAA Compliance Program, HIPAA enforcement, HIPAA's Privacy, Breach, and Security Rules, HIPAA Risk Analysis
11.
 
Data Management and Statistical Issues with Clinical Trials
ID
782493
Dates
25 fév 2016 - 26 fév 2016
Lieu
Miami, Florida, États-Unis
Résumé
This two-day workshop will be conducted by an industry expert who has wealth of experience managing data in clinical trials. After attending this workshop, you can be rest assured that you will be much better equipped in managing data and statistical issues in a compliant way. The tips that the instructor will share during the course of the training program will be invaluable, regardless of where you are in your career.
Contact
Peter Brown;     Tél.: [+1 410-501-5777];     Email.: pbrown@fdamap.com
Sujets
clinical trial, clinical data management, drug development, clinical trial management
12.
 
Medical Device Risk Management A to Z - Best Practices for Effectiveness and Efficiency
ID
789877
Dates
25 fév 2016 - 26 fév 2016
Lieu
San Francisco, États-Unis
Résumé
The course is designed for Medical Products Manufacturers. The course will be taught for Medical Devices and Combination Products, but will also be of benefit to Pharmaceutical Manufacturers.Note:Use coupon code NB5SQH8N and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
ISO 14971 Training, medical device risk management training, medical device risk management best practices
13.
 
Designing and Sustaining New and Existing Product Stability Testing Program
ID
789865
Dates
25 fév 2016 - 26 fév 2016
Lieu
Orlando, États-Unis
Résumé
New or existing modified drug Stability Testing Program's regulations/requirements stipulated by the FDA, 21 CFR or other regulations may sometimes creating an overwhelming situation based on the type of product that is being manufactured. Hence, some manufacturers of new drug products have made inadvertent mistakes in the design of their new drug stability testing program.Note:Use coupon code NB5SQH8N and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
FDA's Drug Stability Testing Program, NDA submission, 21CFR 514.1(b)(5)(x) expectations, Analytical Testing Considerations
14.
 
How to Prepare for an FDA Meeting: Making the Most of Pre-IND/IDE, pre-NDA and Other Critical Meetings
ID
789831
Dates
25 fév 2016 - 26 fév 2016
Lieu
Washington, États-Unis
Résumé
Despite a few guidance documents to help sponsors prepare for meetings with the FDA, it is a challenge to understand the most efficient and productive ways to strategize, prepare, conduct, and follow-up for these meetings. There are many misconceptions about the expectations from these meetings both for the sponsor and the FDA, and hence many sponsors fail to get the most benefit from them. Over the years, the FDA has also revised processes and practices for meeting with sponsors.Note:Use coupon code NB5SQH8N and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
FDA meeting requirements, FDA meetings planning, FDA meeting stages, FDA meeting guidance, meetings with FDA
15.
 
Statistical Analysis for Process and Product Development
ID
789830
Dates
25 fév 2016 - 26 fév 2016
Lieu
San Francisco, États-Unis
Résumé
This course is designed to help scientists and engineers apply statistical methods used assist decision making in process and product development. Variability must be considered when utilizing data to arrive at conclusions. This course will cover Basic Statistics and Graphical Methods used to summarize data.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
Statistical analysis for product development trainings, statistical methods, product development, statistics and graphical methods
Sujets apparentés
16.
 
6th Ubiquitin Research & Drug Discovery Conference
ID
765746
Dates
29 fév 2016 - 01 mar 2016
Lieu
San Diego, États-Unis
Résumé
We are pleased to invite you to GTCbio's 6th Ubiquitin Research & Drug Discovery Conference, which will take place February 29 - March 1, 2016 in San Diego, CA. This conference will provide a forum for researchers from industry and academia to learn about recent advances in basic science and drugs that target the ubiquitin/proteasome system. Hot topics such as autophagy in cancer, developments with deubiquitinating enzymes, and novel drug targets in the ubiquitin system will be covered.
Contact
Kristen Starkey;     Tél.: [16262566405];     Email.: infogtcbio@gtcbio.com
17.
 
11th Protein Kinases in Drug Discovery Conference
ID
765778
Dates
29 fév 2016 - 01 mar 2016
Lieu
San Diego, États-Unis
Résumé
We invite you to attend the 11th Protein Kinases in Drug Discovery Conference, which will take place February 29 - March 1, 2016 in San Diego, CA.
Contact
Kristen Starkey;     Tél.: [16262566405];     Email.: infogtcbio@gtcbio.com
18.
 
Enzymes in Drug Discovery Summit
ID
760866
Dates
29 fév 2016 - 02 mar 2016
Lieu
San Diego, États-Unis
Résumé
We are excited to announce the Enzymes in Drug Discovery Summit, which will take place February 29 - March 2, 2016 in San Diego, CA.

Enzymes have proven to be an important group of drug targets in diseases, and enzyme inhibitors have been among the most successful of drugs. Join us as we discuss ways to overcome drug resistance to these inhibitors, and discuss breakthroughs in targeting historically undruggable enzymes.

Contact
Jessi Huang;     Tél.: [16262566405];     Email.: jessi.huang@gtcbio.com
Sujets
Enzymes in Drug Discovery
19.
 
Pharmacokinetics for Pharmaceutical Scientists Course
ID
725776
Dates
29 fév 2016 - 04 mar 2016
Lieu
San Francisco, États-Unis
20.
 
2nd Protease Inhibitors in Drug Discovery Conference
ID
765742
Dates
01 mar 2016 - 02 mar 2016
Lieu
San Diego, États-Unis
Résumé
We are excited to announce the 2nd Protease Inhibitors in Drug Discovery Conference, which will take place March 1 - 2, 2016 in San Diego, CA.
Contact
Kristen Starkey;     Tél.: [16262566405];     Email.: infogtcbio@gtcbio.com
21.
 
Epigenetic Enzymes in Drug Discovery Conference
ID
765741
Dates
01 mar 2016 - 02 mar 2016
Lieu
San Diego, États-Unis
Résumé
We invite you to attend the Epigenetic Enzymes in Drug Discovery Conference, which will take place March 1 - 2, 2016 in San Diego, CA.
Contact
Kristen Starkey;     Tél.: [16262566405];     Email.: infogtcbio@gtcbio.com
22.
 
Manufacturing and Marketing OTC Drugs in Compliance with FDA Regulations (Updated to address recent Homeopathic Drug announcements by FDA & FTC)
ID
789862
Dates
01 mar 2016 - 02 mar 2016
Lieu
Tampa, États-Unis
Résumé
This interactive one and a half day seminar is intended to help companies understand the legal definitions of cosmetics, drugs, dietary supplements and why certain labeling statements for non-drug products may cause the agency to consider them new drugs without FDA approval.Note: Use coupon code NB5SQH8N and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
Cosmeceuticals, dietary supplements, cosmetics, homeopathic OTCs, FDA regulations
23.
 
Quality Control Laboratory Compliance - cGMPs and GLPs
ID
789916
Dates
03 mar 2016 - 04 mar 2016
Lieu
Tampa, États-Unis
Résumé
FDA inspection and oversight of quality control (QC) laboratories are essential elements of the agency’s evaluation of the compliance status of regulated companies representing multiple industries - pharmaceuticals, biologics, medical devices, as well as foods and cosmetics - as well as the contract QC laboratories which service these industries. Lack of compliance can result in severe regulatory actions, criminal liability, fines, and the inability to obtain product approvals.Note:Use coupon code NB5SQH8N and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
Quality Control Lab regulations, QC Lab regulations, FDA QC Lab requirements, FDA lab regulations, Good Laboratory Practices
24.
 
CDISC Mapping and Strategies Implemented
ID
789882
Dates
07 mar 2016 - 08 mar 2016
Lieu
Philadelphia, États-Unis
Résumé
CDISC requirements to create SDTMs and ADaMs are not easy to understand or apply. There are many rules and standards that must be mastered and maintained across global studies. Pharmaceutical companies and CROs supporting global studies have a need to apply proven methods that reduce confusion and improve documentation. With new members joining the study team, there should be a system to help standardize and automate the FDA submission process.Note: Use coupon code NB5SQH8N and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
CDISC mapping training, OpenCDISC, CDISC datasets, SDTM, ODM, SDM models, ADAM metadata excel file
25.
 
Immune Checkpoint Inhibitors 2016
ID
771774
Dates
15 mar 2016 - 17 mar 2016
Lieu
Boston, États-Unis
Résumé
As the frenzy of preclinical and clinical programs continues, it is critical to take a step back and work out what is working and what is not. At this year’s ICI Boston we are gathering the field’s experts to review the latest research and clinical success of checkpoint modulators. With insights and fresh data from early validation through to clinical strategy we’ve curated the most valuable and important case studies from the last 12 months.
Contact
Jenny Barlow;     Tél.: [1 212 537 5898];     Email.: info@hansonwade.com
26.
 
HIV Vaccines
ID
740120
Dates
20 mar 2016 - 24 mar 2016
Lieu
Olympic Valley, États-Unis
Résumé
HIV Persistence: Pathogenesis and Eradication. The development of a safe and effective HIV vaccine remains a major global health priority and a complex problem to solve. Current efforts emphasize an ability to elicit systemic and mucosal antibody responses capable of preventing the acquisition of infection. Evidence from multiple passive transfer experiments in non-human primates, as well as from studies of immunologic correlates of modest efficacy in the RV144 Thai trial, support the notion that both neutralizing and non-neutralizing antibodies have potential to prevent infection. Major advances have been made in understanding the epitopes, structures and evolutionary pathways of broadly neutralizing antibodies, leading to new avenues to pursue for vaccine design. The extraordinary breadth and potency of some recently discovered neutralizing antibodies has generated additional interest in potential therapeutic applications, including cure strategies. There has also been a steady increase in knowledge of other types of antiviral antibodies and their effector functions that may be important for vaccines. This meeting aims to cover a range of topics including: 1) Initial virus transmission events for vaccine intervention, 2) Non-neutralizing antibody correlates of sterilizing immunity; 3) Epitopes, structures and ontogeny of broadly neutralizing antibodies; 4) Novel vaccine concepts for broadly neutralizing antibody induction; and 5) Immunotherapy. Emphasis will be placed on recent unpublished findings in key areas that hold the greatest promise for rapid progress toward an effective vaccine.
Sujets apparentés
27.
 
Biomarker Summit 2016
ID
744523
Dates
21 mar 2016 - 23 mar 2016
Lieu
San Diego, États-Unis
Résumé
The Biomarker Summit 2016, to be held on March 21-23, 2016 in San Diego, CA at the Westin San Diego Hotel
Contact
Kristen Starkey;     Tél.: [6262566405];     Email.: infogtcbio@gtcbio.com
Sujets
Oncology Biomarkers, Neurological Biomarkers, Inflammatory & Immunological Biomarkers
Sujets apparentés
28.
 
Biomarker Summit
ID
744929
Dates
21 mar 2016 - 23 mar 2016
Lieu
San Diego, États-Unis
Résumé
The Biomarker Summit is a meeting place for leaders in the field to discuss the issues and challenges scientists and researchers face in all aspects of the biomarker and diagnostic development process from discovery to translation to commercialization. A wide variety of important topics will be covered including biomarker identification, validation, and translation strategies, bioinformatics and systems biology approaches to personalized medicine, big data analytics and management, regulatory and reimbursement trends, companion diagnostics development, and much more. Through scientific presentations, case studies and panel discussions, these areas will be addressed in an intimate and highly interactive environment with perspectives from industry, academia and the public sector. Assembling leading scientists, researchers, decision-makers and other players across the industry spectrum, the Summit provides a unique opportunity to gain the latest biomarker developments.
29.
 
Inflammatory & Immunological Biomarkers Conference
ID
744925
Dates
21 mar 2016 - 23 mar 2016
Lieu
San Diego, États-Unis
Résumé
This conference will cover both inflammatory and immunological biomarkers in a wide variety of disease areas. The unmet medical needs in autoimmune diseases, respiratory diseases, kidney disease, lupus, IBD and other inflammatory diseases will be discussed. Presentations and case studies from both industry and academia will cover predictive biomarkers, surrogate endpoints and improving clinical trials as it relates to both drug and diagnostic development. This is an opportunity to listen to recent updates on research, share ideas with colleagues, and network with experts in inflammatory and immunological biomarkers. 
30.
 
Neurological Biomarkers Conference
ID
744946
Dates
21 mar 2016 - 23 mar 2016
Lieu
San Diego, États-Unis
Résumé
This conference focuses on the development of CNS biomarkers for drugs and diagnostics from CSF and Blood, as well as imaging approaches. Scientific data, updates and case studies in neurological and neurodegenerative disorders will be presented on disease areas such as Alzheimer's, Parkinson's and Huntington's. Biomarker challenges for neuropsychiatric disorders such as autism, schizophrenia, depression and mood disorder will also be explored. Attend this event for the opportunity to listen to recent updates on research, share ideas with colleagues, and network with experts to advance biomarker discovery and development. 
31.
 
Ocular Diseases Drug Discovery Conference
ID
744912
Dates
22 mar 2016 - 23 mar 2016
Lieu
San Diego, États-Unis
Résumé
Novel therapeutics from the nanotechnology scope are on the rise. The progress in drug and gene-loaded particles that adequately pass through the mucus barriers provides better delivery to ocular tissue. Recent developments in gene therapies with sustained release of a protein have shown promising results with lesser side effects in patients. The event aims to gather leading scientists, researchers, and experts to discuss and collaborate on combating and curing age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, diabetic macular edema (DME), and other ocular diseases. Other hot topics include PRINT® platform for intraocular prostaglandin formulation, coating technology, anti-angiogenic mechanisms and much more!
32.
 
Modern Phenotypic Drug Discovery: Defining the Path Forward
ID
743867
Dates
02 avr 2016 - 06 avr 2016
Lieu
Big Sky, États-Unis
Résumé
Innovation and productivity in pharmaceutical drug discovery have been below expectations. Surprisingly, more first-in-class small molecule drugs approved by the FDA (1999-2008) were identified by functional approaches reminiscent of pre-genomics pharmacology (phenotypic drug discovery) than by contemporary molecular targeted strategies. This observation, and the unexpected difficulties of target validation, have diminished the impact of the “genomics revolution” and are arguably associated with the decline in innovation and productivity of pharmaceutical research. As a result, pharmaceutical researchers have begun to reevaluate the “Molecular Mindset” which has dominated our collective drug-hunting culture, and explore modern approaches to phenotypic screening. However, there is currently no single scientific forum where scientists from pharma, biotech, academia and instrument/service providers can meet and discuss strategies/issues related to phenotypic drug discovery (PDD). In part, this is because PDD encompasses multiple therapeutic areas and involves diverse disciplines including drug discovery, chemistry, cell biology, stem cell biology, systems biology, genomics, bioengineering and informatics. This Keystone Symposia meeting uniquely provides this interdisciplinary environment and is a particularly attractive venue given the increasing role of academia in drug discovery research. The conference will be a forum for the global PDD research community in which scientists from diverse institutions and scientific disciplines can meet to share/discuss/debate topics related to advantages/disadvantages of PDD and how PDD can complement targeted approaches. Significantly, the conference will provide a much needed forum for the growing interest in PDD, and can conceivably become the cornerstone of the global scientific movement for the reintroduction of functional biology/physiology-driven pharmaceutical research.
Sujets apparentés
33.
 
New Therapeutics for Diabetes and Obesity
ID
743958
Dates
17 avr 2016 - 20 avr 2016
Lieu
La Jolla, États-Unis
Résumé
Type 2 diabetes (T2DM) is a global pandemic with approximately 350 million patients worldwide, driven largely by increasing prevalence of obesity. Multiple options exist for treatment of the primary disease and the array of associated cardiovascular disorders. Nonetheless, the majority of patients do not reach recommended glycemic goals, and there is an urgent need for more efficacious, cost-effective and safe therapies. The regulatory hurdle for new drugs is sizable and challenged by the specific requirement for cardiovascular mortality study. Given the magnitude of the challenges, highly collaborative efforts involving academia, biotech, pharma, regulatory agencies, patient advocacy groups and other key stakeholders are required to identify and advance new therapies that are substantially differentiated from current disease management. The major goals of this meeting are to: 1) Define the distance between current therapy relative to what is most needed to address successfully the near-term challenges of the disease and the wave of later-stage disease-specific complications; 2) Communicate the most important scientific advances in metabolic diseases with the intimate details that often escape peer-review publication and are seminal to drug R&D; and 3) Create opportunities for candid discussion among key stakeholders (academia, biotech, industry, regulatory, venture community, etc.) to identify new business processes, along with new science to streamline the successful conversion of ideas to medicines. Is it anticipated that the perspectives and science presented at this meeting, together with multiple platforms for discussion and interaction, will facilitate the identification of collaborations and opportunities for the discovery of transformative treatment of diabetes and related disorders. The meeting will be uniquely led by experienced drug-hunters with world-class academic credentials to help foster the translation of basic science to breakthrough therapeutics. We anticipate that this meeting will be of interest to a broad and diverse group of individuals interested in drug discovery and cost-effective development with an emphasis on quality, speed and value.
Sujets apparentés
34.
 
DCH — Drug Discovery Chemistry
ID
784772
Dates
19 avr 2016 - 22 avr 2016
Lieu
San Diego, Californie, États-Unis
Résumé
Drug Discovery Chemistry is a dynamic conference for medicinal chemists working in pharma and biotech. Focused on discovery and optimization challenges of small molecule drug candidates, this event provides many exciting opportunities for scientists to create a unique program according to personal interests. New for 2016 will be the addition of three symposia on Friday covering the blood-brain barrier, biophysical approaches for drug discovery, and antivirals.
Contact
Tél.: [7819725400];     Email.: chi@healthtech.com
Sujets
drug discovery, drug development, chemistry, proteins, peptides, macrocyclics
35.
 
World Orphan Drug Congress USA 2016
ID
728903
Dates
20 avr 2016 - 22 avr 2016
Lieu
Washington, DC, États-Unis
Résumé
This is the largest global industry gathering for the orphan drug industry and rare disease community where pharma, biotech, patient groups, academia, regulators, payers and investors gather to talk about strategies to expedite orphan drug development. We grew the event to 600 participants in 2015 with over 25 countries represented. cademic medical centers, HCPs, clinicians and point of care diagnostics will be a new focus in 2016. Specific orphan products and their Marketing Managers will also be a stronger focus along with gene therapy as the future rare disease cure. Meet CEOs, VPs and Directors of the following business units from pharma and biotech: R&D, Business Development, Regulatory Access, Market Access, Commercial, Marketing and Brand/Product Managers.You will also meet Scientists, Investigators and Engineers as well as relevant Heads from university departments studying rare disease and developing a cure.
Contact
Freya Smale;     Tél.: [646-619-1811];     Email.: freya.smale@terrapinn.com
Sujets
In terms of content, people are talking more and more about gene therapy orphan drugs. 2016 will feature the latest content on gene therapy orphan drugs in development. The other new addition to 2016 is a workshop for clinicians. This workshop is designed to enable marketers to help clinicians get educated on rare diseases and orphan drugs so they can detect and diagnose rare diseases better and faster.
36.
 
Stem Cell Research & Regenerative Medicine Conference
ID
744998
Dates
25 avr 2016 - 26 avr 2016
Lieu
Boston, États-Unis
Résumé
This conference presents information regarding cutting-edge developments in all areas of stem cell research, including the biology, medicine, applications and regulations of stem cells. Topics of discussion include recent developments in pre-clinical and clinical trials of stem cell therapy, regenerative medicine and tissue engineering, cancer stem cells, immunotherapy, stem cell reprogramming, and regulatory policies regarding stem cell research.
Sujets apparentés
37.
 
Pre-Filled Syringes East Coast
ID
770776
Dates
25 avr 2016 - 26 avr 2016
Lieu
Iseline, New Jersey, États-Unis
Résumé
Through a combination of powerful keynote addresses, topical debate and interactive workshops, Pre-Filled Syringes East Coast will once again play host to an audience of senior scientists, device manufacturers and PFS market professionals, providing a focal point to discuss the latest innovations and developments in pre-filled syringes; as well as honing in on industry challenges and regulatory compliance.
Contact
Teri Arri;     Tél.: [+44 (0)20 7827 6000];     Email.: tarri@smi-online.co.uk
Sujets
prefilled syringes, autoinjectors, human factors, extractables, leachables, patient safety, compliance, biosimilar, parenteral, packaging, injectable devices, drug device, drug delivery, combination products, sterilization, needle, component, glass syringe, cop syringe, container, formulation, manufacturing, medical device, parenteral drug, plastics, quality by design
38.
 
Stem Cell Summit
ID
744953
Dates
25 avr 2016 - 27 avr 2016
Lieu
Boston, États-Unis
Résumé
Stem Cell Summit provides cutting-edge information on developments in all areas of stem cell research from bench to bedside, including the biology, medicine, applications, regulations, product development, and the commercialization of stem cells. Recent developments in pre-clinical and clinical trials of stem cell therapy, regenerative medicine and tissue engineering, cancer stem cells, immunotherapy, stem cell reprogramming, regulatory policies regarding stem cell research, and manufacturing will all be discussed. Business opportunities, challenges, and potential strategies for overcoming these challenges will also be addressed.
Sujets apparentés
39.
 
2016 Diabetes Summit — 2016 Diabetes Summit
ID
766548
Dates
25 avr 2016 - 27 avr 2016
Lieu
Boston, États-Unis
Résumé
GTCbio and the advisory board would like to invite you to the 2016 Diabetes Summit to be held April 25-27, 2016 in Boston, MA. This unique event encompasses the drug discovery and partnering aspects of diabetes in two individual conferences that take place concurrently: 9th Diabetes Drug Discovery & Development Conference & 6th Diabetes Partnering & Deal-Making Conference.
Contact
Kristen Starkey;     Tél.: [16262566405];     Email.: infogtcbio@gtcbio.com
Sujets apparentés
40.
 
Lyophilization USA
ID
781499
Dates
27 avr 2016 - 28 avr 2016
Lieu
Iselin, États-Unis
Résumé
Lyophilization USA 2016 will gather leading market experts to discuss the latest cutting edge developments in freeze drying as well as solutions to on-going industry challenges. The packed agenda features a mix of case study led presentations, panel debates, interactive workshops and keynote addresses that have been tailored for an audience of professionals working in pharmaceutical lyophilization from formulation development through to production and quality assurance. Featured Speakers include Pfizer, Genzyme, Allergan, Novo Nordisk A / S, Johnson & Johnson, Steritech Solutions LLC, Biogen Idec, Momenta Pharmaceuticals, PLUS MANY MORE!
Contact
Teri Arri;     Tél.: [+442078276000];     Email.: tarri@smi-online.co.uk
Sujets
lyophilisation, quality by design, freeze drying, scale-up, validation, spray drying, Process Analytical Techniques, PAT, robustness, stability, delivery, optimisation, protein stabilisation, design strategies, maintenance, automatic loading and unloading, lyophilization, qbd, protein, optimization, aseptic, fill/finish, temperature, drying, powder, nucleation, sterilization, injectables, thaw, storage, crystallization, formulation, parenteral
41.
 
5th Annual Drug Repositioning, Repurposing and Rescue Conference
ID
759937
Dates
21 jui 2016 - 22 jui 2016
Lieu
Chicago, États-Unis
42.
 
FASEB SRC: Translational Neuroimmunology: From Mechanisms to Therapeutics
ID
786115
Dates
24 jul 2016 - 29 jul 2016
Lieu
Big Sky, Montana, États-Unis
Résumé
This FASEB Science Research Conference will bring a greater understanding of the biochemical and molecular mechanisms underlying diseases associated with dysfunction in the neuroimmune system will undoubtedly facilitate the translational aspect of this field as novel therapeutic targets are moved towards human clinical trials. This will be facilitated by cutting-edge talks from scientists with international reputations on the topics of 1) CNS Metabolism and the Microbiome; 2) Inflammation in the Peripheral Nervous System; 3) Stem Cells and Neuroinflammation; 4) Neuroinflammatory Mechanisms of Demyelinating Diseases; 5) Immunity and Neurodegenerative Diseases; 6) Pre-clinical Studies for CNS Neuroinflammatory Diseases; 7) Neuroinflammation and Neurotrauma; 8) Neuroinflammation and Host Defense; and 9) The Many Faces of Microglia. In addition, this SRC will host a pre-meeting workshop entitled
Contact
FASEB SRC Staff;     Tél.: [3016347010];     Email.: SRC@faseb.org
Sujets apparentés

États-Unis: liste de tous les évènements/conférences.

LYOPHILIZATION USA
PAIN THERAPEUTICS
RNA Therapeutics
Superbugs & Superdrugs - Pushing financial incentives and collaborative incentives to accelerate clinical success
Pre-Filled Syringes East Coast

Bon à savoir...

Vous pouvez insérer un encadré afin de diffuser vos évènements et services dans cet espace.

Dernière mise à jour: 30 Octobre 2079